NDORMS researchers join five other universities to investigate how cancer survivors make antibodies that target and destroy tumours, and explore routes for new treatments
A new study published in Nature Communications identifies a key driver of joint and intestinal inflammation that could lead to future treatment of the chronic inflammatory disease.
A new study published in the Journal of Experimental Medicine reveals how IL-10 and PGE2 work together to prevent inflammatory tissue damage and maintain a healthy gut balance
Jagdeep Nanchahal, Professor of Hand, Plastic and Reconstructive Surgery at the Kennedy Institute, and his team have won the International Dupuytren Award for a trial repurposing anti-TNF in Dupuytren\u2019s disease.
New research from Dr Richard Williams\u2019 group at the Kennedy Institute suggests a route for the development of more selective \u2013 and effective \u2013 therapies for immune-mediated inflammatory disease.
When immune cells detect harmful pathogens or cancer, they mobilise and coordinate a competent defence response. To do this effectively immune cells must communicate in a way that is tailored to the pathogenic insult. Consequently, the body's response to various health challenges depends on successful coordination among the cells of the immune system.
Oxford is the newest partner of the national Research into Inflammatory Arthritis Centre Versus Arthritis (RACE) which has been awarded continued funding of nearly \u00a32m over the next five years from Versus Arthritis.
The Kennedy Trust for Rheumatology Research (KTRR) has pledged a minimum of \u00a320M over five years to the Kennedy Institute of Rheumatology at the University of Oxford to support pioneering research into chronic inflammatory disease.
The Kennedy Institute recently hosted a visit from the National Rheumatoid Arthritis Society (NRAS) to explore opportunities to partner on patient involvement approaches in arthritis research.
Congratulations to Kennedy researchers Professor Chris Buckley, Professor Mark Coles and Dr Stephen Sansom who have been awarded \u00a31.5M funding from the Medical Research Council (MRC) to explore fibroblasts as an emerging target to treat chronic inflammatory disease.
Pioneering research by scientists at the Universities of Oxford and Birmingham published today in Nature brings us a step closer to developing targeted therapies for inflammatory diseases.
Dr Fiona Watt has been awarded a prestigious UK Research and Innovation (UKRI) Future Leaders Fellowship to further her research for better treatments for people living with, or at risk of the commonest form of arthritis, osteoarthritis.
Two articles from the Kennedy Institute review the latest in understanding immune control in the gut and skin and explain how this knowledge is being translated into new treatments for inflammatory disease
Oxford researchers gathered at the Kennedy Institute earlier this month to learn how advanced imaging technologies, such as super resolution microscopy, are pushing the boundaries of scientific discovery.
A recent workshop at Pembroke College, Oxford, provided a showcase for research within the Arthritis Therapy Acceleration Programme (A-TAP) aimed at speeding up the delivery of new drugs for immune-mediated inflammatory disease (IMIDs).
![](\"https://www.kennedy.ox.ac.uk/news/new-collaboration-will-help-researchers-understand-why-cancer-survival-between-patients-differs/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n